We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

25 hedge funds and large institutions have $4.4M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

54% more capital invested

Capital invested by funds: $2.86M → $4.4M (+$1.54M)

47% more funds holding

Funds holding: 1725 (+8)

Holders
25
Holders Change
+8
Holders Change %
+47.06%
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
6
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
+$220 +7 +700%

FRTX Hedge Fund Activity: Q4 2020 in Review

25 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2020, worth a combined $4.4M — up 54% from $2.86M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FRTX positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $931K. The largest seller was Sabby Management, exiting entirely with an estimated $652K sold.

  • 25 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2020, up from 17 in Q3 2020.
  • Funds reported $4.4M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2020, up 54% quarter-over-quarter.
  • 11 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +8 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2020 was Anson Funds Management, an estimated $931K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2020 was Sabby Management, an estimated $652K sold.

Based on aggregated 13F filings for Q4 2020.